Botulinumtoxin A as a treatment for myalgia and myofacial pain in patient with temporomandibulardisorders – a quality study associated to a new treatment routine. - BTXclinicaltrialEA

Region Stockholm Folktandvarden0 个研究点目标入组 1 人开始时间: 2023年10月26日最近更新: 2024年7月22日

适应症

试验速览

暂无简介。

•a) Female gender b) age 18-45 years c) diagnos of myalgia, myofacial pain or myofascial pain with refered pain according to DC/TMD d) an average pain due to NRS = 3 for more than three months e) treatment for orofacial pain > three months ago.f) with adequate contraceptives and a negative pregnancy test. Patients will still be included even if they have one or more co-diagnoses 1) Discdisplacement with or without reduction according to DC/TMD 2) degenerative joint disease 3) arthralgia

•1) treatment with BTX during the last six months 2) treatment for orofacial pain within the last 3 months. 3) systemic inflammatory diseases (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis) 4) fibromyalgia 5) neuropathic pain 6) neurologic disease (myastenia gravis) 7) pain of dental origin 8) use of muscle relaxants or aminoglycoside antibiotics 9) pregnancy or nursing 10) hypersensitivity to BTX 11) neuropsychiatric conditions.12) difficulties understanding the Swedish language.13) Trauma to head, neck or face, including orthognatic surgery

发起方

Region Stockholm Folktandvarden